FC for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Journal Title: Biomedical Journal of Scientific & Technical Research (BJSTR) - Year 2018, Vol 19, Issue 4
Abstract
Despite overall improvements, relapsed/refractory diffuse large B-cell lymphoma (DLBCL)remains a major cause of morbidity [1]. Treatment option for relapsed/refractory DLBCL is salvage chemotherapy followed by an autologous hematopoietic cell transplantation(auto-HCT) for those with chemotherapy-sensitive disease [2], but prognosis is generally poor. Currently, there is no standard salvage chemotherapy regimens, and the use of new therapies for relapsed disease require further evaluation. Based on the landmark PARMA trial [2], high-dose chemotherapy and auto-HCT were firmly considered as the optimum salvage treatment in relapsed chemosensitive DLBCL. Numerous salvage chemotherapy regiments have been used, with a high response rate, low hematologic and nonhematologic toxicity. They broadly are divided into regimens based on ifosfamide, cytarabine/platinum, or gemcitabine [3], and other new drugs such as radiolabelled immunotheraphies [4]. In addition to these commonly used chemotherapy regimens, we explored some rare chemotherapy regimens. We evaluated safety and antitumor activity of the chemotherapy regimen of FC (fludarabine, cyclophosphamide) for six patients with relapsed/ refractory DLBCL. Clinical data of 6 relapsed and refractory DLBCL patients treated with FC in CHONGQING University Cancer Hospital between Feb 1.2018 and Dec 31.2018 were retrospectively analyzed. 6 patients occurred at an average age of 52.8 years. Among the 6 patients, 2 cases were transformed from follicular lymphoma and 2 from marginal lymphoma, 2 of them were relapsed DLBCL while the other 4 were refractory. There were 3 patients used rituximab combined with FC. None of them had a transplantation before the regiments. All the patients received fludarabine with 25mg/m2 on days 1 to 3 and cyclophosphamide 300mg/m2 on days 1 to 3. After 2 to 3 cycles, we researched the ORR was 83%(5/6), with 2 patients achieving a complete response(CR) and 3 a partial response(PR). The major adverse events included thrombocytopenia (66.7%), neutropenia (33.3%), anemia (50%) and nausea/vomiting (33.3%), 1 patient had upper respiratory tract infection during the treatment period. There was no chemotherapy-related death occurred. The chemotherapy regimen of FC is effective in refractory and relapsed DLBCL, as well as safe and well-tolerated. Usually, the chemotherapy regimen of FC is used in chronic lymphocytic leukemia (CLL) and it is rarely reported in relapsed/refractory DLBCL. Our case is not large enough to perform statistical analysis, however, our findings explore a new possibility of traditional method. Further studies are required to practice.
Authors and Affiliations
Bingling Guo, Qiying Li, Qingqing Huang, Xiping Liang, Chunyan Xiao, Dehong Huang, Tao Yang, Wenjun Zhang, Yingyu Nan, Ying Xiang
Keywords
Related Articles
- EP ID EP622497
- DOI 10.26717/BJSTR.2019.19.003344
- Views 193
- Downloads 0
A System and Method for Non-Invasive Measurement of Cardiovascular Blood Pressure
A system and method for the non-invasive portable ultrasound-based measurement system of the Cardiovascular blood pressure is presented, wherein the blood pressure measurement model is calibrated to the simultaneous dire...
Port site Metastasis in Prostate Cancer after Laparoscopic Radical Prostatectomy: A Case Report
Background: The port site metastasis in prostate cancer(PCa) after laparoscopic radical prostatectomy(LRP) is an uncommon metastatic pattern of PCa. Case presentation: We described an 81-year-old male patient who was adm...
Primary Cilium, a Potential Target of Microgravity Induced Bone Loss
Microgravity in space can cause various problems in different biological systems. One of the most prominent and well recognized physiological challenges accompanying an extended spaceflight is the reduction in bone mass...
Determination of Plasma Tissue Factor Antigen and Tissue Factor-Bearing Microparticles Activity in Healthy Subjects
Background: Tissue factor (TF) is an integral membrane protein, normally separated from the blood by the vascular endothelium, which plays a key role in the initiation of blood coagulation. TF is present in plasma in var...
β-HCG as a Tumor Biomarker with Special Reference to Breast Cancer
Introduction Human chorionic gonadotropin (HCG) is a placental protein hormone initially secreted by cells (syncitiotrophoblasts) from the implanting conceptus. It supports the ovarian corpus luteum, endometrial lining a...